Capitainer inks European and Asia Pacific distribution deal with Speciality Diagnostix for qDBS dried blood spot sampling system
Stockholm, September 16, 2020: Swedish med-tech start-up Capitainer today announced it has signed a distribution deal with Speciality Diagnostix for Europe and Australia/New Zealand. The deal comes amid increasing interest driven by COVID-19 in Capitainer’s highly accurate qDBS dried blood spot sampling system.
Christiaan E Raaijmakers, European General Manager, and Anthony May, Asia Pacific General Manager for Specialty Diagnostix commented: “With their standardized, microsystem based sampling technology, Capitainer SE have developed a ground-breaking solution for near-patient blood sampling of volume defined Dried Blood Spots (DBS). Patients are able to conveniently collect their own blood samples at home and mail them to a laboratory for analysis using an innovative DBS card that allows the sampling of an exact volume of blood regardless of the sample’s haematocrit. We are very delighted to represent Capitainer and will it leverage our expertise and marketing possibilities in the Drugs of Abuse and Therapeutic Drug Monitoring markets in particular.”
Christopher Aulin, CEO of Capitainer added: “Specialty Diagnostix is an ideal partner for us. They are dedicated to the marketing and distribution of novel, laboratory based assays and active in 25 markets, directly serving 15 European and Asia Pacific countries. They will help us meet strong interest for qDBS across the wide range of both existing and new applications such as therapeutic drug monitoring, genomics anti-doping testing we had originally identified. In addition, we are working with several groups involved in COVID-19 testing and planning to launch antibody testing in Sweden together with several health care regions.”
Capitainer’s qDBS system is designed to enable patients to collect their own volume defined dried blood spot at home. The patented smart chip ensures exact sample volumes of 10ul with low CV, independent of haematocrit. Patients simply place their finger over the inlet port on the qDBS card which automatically fills a microchannel with the required amount and discards any excess. The potential for human error is thus completely eliminated. Subsequently, the blood volume contained in the microchannel automatically transfers to the specimen collection membrane, forming an accurate and high quality dried blood spot sample, preserved for quantitative bioanalysis. The filled card can then be safely transported to the point of testing without the need for refrigeration or specialised packaging.
-ends-
For more information visit www.capitainer.se
ContactsChristopher Aulin, CEO t: +46 708 977 577 e:aulin@capitainer.se
Media
Richard Hayhurst/Ola Bjorkman
Notes to editors
Captainer AB is a Swedish med-tech company founded in 2013 by Professor Olof Beck from the Department of Clinical Pharmacology, Karolinska Institutet and Professors Göran Stemme & Niclas Roxhed, Micro and Nanosystems, Royal Institute of Technology (KTH), Sweden). Capitainer is a supplier of intelligent solutions for Dried Blood and Plasma Spot sampling with the market’s best volume accuracy serving several market segments, including but not limited, to Therapeutic Drug Monitoring, Biomarkers, Drug Development and Drugs of Abuse and Doping. By using a combination of paper- and polymer microfluidics the precision and accuracy of metering of capillary blood is on par with that of a standard displacement pipette. Thus, the technology enables more convenient solutions for patients’ home sampling ensuring more reliable test results for healthcare and other providers of tests based on blood or plasma.